D. E. Shaw & Co., Inc. Essa Pharma Inc. Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Essa Pharma Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 63,481 shares of EPIX stock, worth $434,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,481

Previous 65,081 2.46%

Holding current value

$434,844

Previous $552,000 39.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.63 - $8.42 $7,408 - $13,472	-1,600 Reduced 2.46%	63,481 $333,000
Q1 2024 May 15, 2024	SELL	$6.17 - $10.65 $830,309 - $1.43 Million	-134,572 Reduced 67.4%	65,081 $552,000
Q4 2023 Feb 14, 2024	BUY	$2.74 - $7.35 $86,592 - $232,282	31,603 Added 18.81%	199,653 $1.32 Million
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.34 $10,844 - $13,931	-4,171 Reduced 2.42%	168,050 $453,000
Q1 2023 May 15, 2023	SELL	$2.56 - $3.55 $200,099 - $277,482	-78,164 Reduced 31.22%	172,221 $511,000
Q4 2022 Feb 14, 2023	SELL	$1.5 - $4.82 $374,172 - $1.2 Million	-249,448 Reduced 49.91%	250,385 $630,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.44 $278,612 - $547,672	159,207 Added 46.74%	499,833 $910,000
Q2 2022 Aug 15, 2022	BUY	$3.15 - $7.94 $125,477 - $316,281	39,834 Added 13.24%	340,626 $1.07 Million
Q1 2022 May 16, 2022	BUY	$6.18 - $14.44 $1.03 Million - $2.4 Million	166,278 Added 123.61%	300,792 $1.86 Million
Q4 2021 Feb 14, 2022	SELL	$7.8 - $14.38 $1.41 Million - $2.61 Million	-181,217 Reduced 57.4%	134,514 $1.91 Million
Q3 2021 Nov 15, 2021	BUY	$7.76 - $29.37 $2.45 Million - $9.27 Million	315,731 New	315,731 $2.53 Million

Others Institutions Holding EPIX

# of Institutions

Shares Held

35.2M

Call Options Held

37.7K

Put Options Held

3.8K

View Full List

About ESSA Pharma Inc.

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $302M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

More about EPIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account